u-Lipid metabolism of an intracerebrally implanted brain tumor and normal brain was investigated in awake Fischer 344 rats using intravenously injected [9,10-3H]-palmitate as a probe. A suspension of Walker 256 carcinosarcoma cells (250 cells in 5 ~zl medium), with or without 1% low-melting-point agar, was implanted into the caudate nucleus of rats 8 to 9 weeks old. Control animals received an intracerebral injection without tumor cells. Seven days after implantation, awake rats were infused intravenously for 5 minutes with [9,10-3H]-palmitate (6.4 mCi/kg). The rats were killed 20 minutes after initiation of the infusion and coronal brain slices were obtained for quantitative autoradiography and light histological study. Tumor cell masses were histologically well demarcated from the surrounding brain tissue. Tumor tissue incorporation of [9,10-3H] -palmitate was heterogeneous, ranging on average from 3.1-to 6.1-fold greater than in the corresponding contralateral brain. In addition, incorporation corresponded to regional tumor cell density. The incorporation rate constant of [9,10-3H]-palmitate in tumor was significantly increased compared to control brain and was independent of tumor size. Necrotic areas within tumors showed no incorporation of radiolabeled palmitate. Brain surrounding the tumors and control injection sites showed reactive gliosis, and possessed 30% greater incorporation of [9,10-3H]-palmitate than contralateral normal brain. These results suggest that [9,10-3H] -palmitate can be used to image brain tumors in vivo, measuring turnover and/or synthesis of tumor and brain lipid.
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IPID composition and metabolism of brain tu- 5 12 14~1243139 | mors have been widely investigated. 9 ........ l__,/ 34,42 It is also known that dividingcells, such as neo_ plastic cells, synthesize cell membrane constituents including phospholipids more rapidly than do nondividing cells. 16,27.39 A number of studies also indicate that phospholipid composition and the fatty acid composition of phospholipids differ between brain tumors and normal brain) 2ta'2L24"3~. 34 Indeed, it has been shown that the composition of some tumor cell lipids is related to tumor cell origin and/or malignancy? '42 These findings suggest that the phospholipid composition and metabolism of brain tumors can differ from the composition or metabolism of normal brain, and that some aspects of phospholipid metabolism may reflect the tumor pathology. This interpretation has been examined to a limited extent in cultured tumor cell lines, 4'6'3~ but quantitative studies have not been performed to examine this interpretation in vivo.
Our laboratory has developed an in vivo procedure to study brain lipid metabolism, including phospholipid synthesis and turnover, by quantitative autoradiography and biochemical analysis following the intravenous injection of one of several radiolabeled fatty acids. 7' ~' ~7,20~26 Injection of a radiolabeled fatty acid essentially pulse-labels brain lipids, particularly specific phospholipids. By means of an operational equation applied to the data, rates of incorporation of tracer from plasma into brain can be quantitated. TM This fatty acid incorporation model has been used to examine brain lipid metabolism during development 35 and nerve regeneration. 4~ For example, incorporation of radiolabeled palmitate into the brain of a 20-day-old rat is sevenfold higher than into the adult rat brain. Incorporation into white matter of the developing rat brain is elevated, particularly during the period of rapid myelin synthesis. 35 Likewise, regeneration of the hypoglossal nerve following axotomy is accompanied by increased incorporation of radioactive palmitate into the ipsilateral hypoglossal nucleus. 4~ These findings indicate that increased membrane synthesis in vivo is accompanied by increased incorporation of a plasmaderived fatty acid into brain structural elements.
Palmitate is incorporated mainly into brain membrane phospholipids, particularly into phosphatidylcholine.J L26 We therefore hypothesized that radiolabeled palmitate could be used to image a growing intracerebral tumor mass by quantitative autoradiography and to distinguish it from normal brain. To examine this hypothesis, we implanted Walker 256 earcinosarcoma tumor cells into the brain of rats, as a model of a metastatic brain tumor.~3 At 7 days after tumor implantation, [9,10-3H]-palmitate was injected intravenously into awake rats to determine its rate of incorporation at an early stage of tumor development. We also examined [9,10-3H]-palmitate incorporation into brain around tumor, into brain following sham lesioning, and into brain regions normally lacking an intact bloodbrain barrier, to identify which changes specifically occur in tumor tissue. An abstract of this work has been presented. 22
Materials and Methods
Animal experimentation and care followed the National Institutes of Health "Guide for the Care and Use of Laboratory Animals." Walker 256 carcinosarcoma tumor cells were maintained subcutaneously in the flank of Wistar rats.13 On the day of brain implantation, tumor was prepared as a single-cell suspension, 250 cells in 5 ul of Dulbecco's modified Eagle's tissue culture medium* with or without 1% low-melting-point agar. Agar was used to reduce the number of cells that disseminate extracerebrally during intracerebral injection. ~8 The suspension was implanted into the brains of male 8-to 9-week-old Fischer 344 rats.t Each rat was anesthetized with intraperitoneal sodium pentobarbital (50 mg/kg) and placed in a stereotactic apparatus.~ A midline scalp incision was made and a burr hole was created in the right frontal skull using a dental drill. Tumor cells, with or without agar, were then implanted into the right caudate nucleus using a No. 30 T. Nariai, et al.
By 7 days after tumor or agar implantation, each rat was anesthetized with 1.5% halothane, and polyethylene catheters were inserted into a femoral artery and vein. The rat was restrained in a loosely fitting body cast and was allowed to recover from anesthesia for 4 hours. Blood pressure, heart rate, and hematocrit were recorded via the arterial catheter. The [9,10-3H]-palmitate (total amount 6.7 mCi/kg body weight) was infused intravenously at a rate of 400 ul/min for 5 minutes. Timed blood samples were collected to determine [9,10-3H]-palmitate radioactivity in plasma, as described elsewhere. 26 Twenty minutes after the start of infusion, the animal was killed by an intravenous overdose of sodium pentobarbital; the brain was removed rapidly and frozen in 2-methylbutane cooled to -50"C.
Frozen brains were cut in a cryostat at -20~ and sequential triplicate coroneal sections, 20 ,m thick, were used alternately for autoradiography and for staining with cresyl violet for histological examination. Brain sections for autoradiography were placed on a cover glass and exposed to x-ray film, together with 3H-microscale standards for 8 weeks.II Brain regions and areas of tumor in the autoradiographs were identified from adjacent histological sections. Tumor size was estimated by measuring the maximum cross-sectional area (in sq mm) of tumor tissue in the crcsyl violetstained sections. Radioactivity expressed as mCi/gm tissue was determined quantitatively using a microcomputer-linked image analyzer.* The regional incorporation rate constant (k') for radiolabeled fatty acid was calculated as follows, based on a previously described mathematical model: TM C'br ~20min C'pl dt where k* is in units of ml/sec/gm, C'br (in units of nCi/gm) is brain radioactivity at 20 minutes. C*pl (in units of nCi/ml) is plasma fatty acid radioactivity, and t is time after start of infusion. All values are presented as means _ standard errors of the means. Statistical significance was determined by paired t-statistics, by Dunnett's t-statistics for multiple comparisons] ~ and by regression analysis, considering p < 0.05 as significant.
Results
As illustrated in Fig. 1 , intracerebral tumor masses of 0.15 to 15.3 sq mm in maximum cross-sectional area (mean 4.9 sq mm) were observed within 7 days after the implantation into rat brains of Walker 256 carcinosarcoma cells in agar. On cresyl violet-stained sections, tumor areas were easily distinguished from II X-ray film manutitctured by LKB Instruments, Gaithersburg, Maryland; 3H-microscale standards supplied by Amersham Corp., Arlington Heights, Illinois.
* Microcomputer-linked image analyzer manufactured by Brock University, St, Catherines, Ontario, Canada. brain tissue, which showed reactive gliosis in the regions adjacent to tumor. Implantation without agar produced smaller tumor masses (0.04 to 0.27 sq mm, mean 0.14 sq mm) with tumor cells observed primarily in the needle track at the injection site.
Autoradiographs of brain regions with large tumors showed substantially more uptake of [9,10-3H]-palmirate in the tumor areas than in surrounding brain. The shape of the tumor mass, delineated by the increased radioactivity incorporated, corresponded to its anatomical location and shape on adjacent histological sections (Fig. 1 ). Brain regions adjacent to the tumor mass showed slightly greater radioactivity than in the uninjected contralateral brain, but substantially less than tumor radioactivity.
Incorporation of [9,10-3H]-palmitate into tumor was heterogeneous (Fig. 2) . Comparisons of autoradiographs and histological sections (Fig. 2) indicated that tumor areas of greater radioactivity coincided with areas of relatively high tumor cell density, whereas tumor areas with decreased or minimal radioactivity corresponded to areas of lower cell density or necrosis. Even when tumor ceils did not form a large mass and were present only near the needle track, there was increased radioactivity (Fig. 3A) , which exceeded that observed in areas of reactive gliosis at control lesion sites (Fig. 3B) . Although the tumor illustrated in Fig.  3A is the smallest tumor that was observed (0.04 sq mm maximum cross-sectional area), it showed a 4.18-fold greater radioactivity than did the contralateral brain. The increased radioactivity was restricted to the histologically defined tumor regions. Table 1 summarizes regional rates of incorporation of radioactive palmitate into tumor and brain, as well as normalized incorporation rates using the brain region contralateral to the tumor and lesion as a reference. Tumor incorporation of [9,10-~H]-palmitate was measured in regions of highest and lowest radioactivity to express heterogeneous incorporation. The incorporation rate constant (k') of the tumor area (between 6.23 _+ 1.02 and 11.82 _ 1.76 ml/sec/gm • 104) was significantly greater than in contralateral brain regions (2.03 _+ 0.22 ml/sec/gm • 104, p < 0.01 highest range, p < 0.05 lowest range). Rates of incorporation were 3.06 to 6.07 times those in the corresponding contralateral brain regions. Incorporation of palmitate radioactivity in areas of reactive gliosis in control lesions and into brain adjacent to the tumor was 1.3-fold that of the contralateral brain. Although the values were significantly higher than in the contralateral brain (p < 0.01), incorporation rates were substantially less than in the tumor. As the rate of increase of k* in control injec- The relationship of [9,10-3H]-palmitate incorporation to size of tumor is illustrated in Fig. 4 . There was no significant correlation between the size of tumor and k ~ either in the group implanted with agar (p > 0.05, r = -0.6) or in the group implanted without agar (p > 0.05, r = -0.7) (Fig. 4) .
Incorporation of [9,10-3H]-palmitate by the pineal gland, subfornical organ, and median eminence was measured in tumor-bearing rats to evaluate incorporation into brain regions lacking an intact blood-brain barrier and containing a fenestrated capillary endothelium. 29 In 10 rats the mean rates of incorporation divided by rates in brain contralateral to tumor were as follows: subfornical organ 2.23 + 0.32; median eminence 2.68 _+ 0.30; and pineal gland 2.97 + 0.25. These rates were smaller than in tumor regions, which had high incorporation values of between 3.06-and 6.07-fold those of contralateral brain.
Discussion
This is the first report of the use of an intravenously injected radiolabeled fatty acid to image a brain tumor 
Sign ificances of Increased Incorporation ( f [9, lO-3H]-Palmitate into Tumor
Prior studies from our laboratory have shown that intravenously injected [9,10-3H]-palmitate is rapidly incorporated into the lipid fraction of brain, constituting 83% of dried brain radioactivity. The incorporated radioactivity is present primarily in phospholipids, the main constituents of cell membranes, and reaches a maximum value in brain within 5 to 15 minutes after intravenous injection. 26 These properties make [9,10-3H]-palmitate a suitable imaging tool to examine membrane phospholipid (particularly phosphatidylcholine) t The highest and lowest radioactivity areas in the tumor were measured for each tumor-bearing rat. Areas of necrosis were excluded because they had the same radioactivity as the film background.
:~ Radioactivity in tumor tissue and the area adjacent to tumor were corrected using this radioactivity.
w Radioactivity in control lesion was corrected using this radioactivity.
synthesis and turnover quantitatively in vivo, using the fatty acid incorporation model described elsewhere] '36
Previous studies have demonstrated greater incorporation of radiolabeled palmitate into the developing rat brain as compared to the adult brain, 35 and into the hypoglossal nucleus of the rat following axotomy of the ipsilateral hypoglossal nerve? ~ In both instances, new cell membrane is rapidly synthesized, reflecting elaboration of brain myelin and nerve fiber regeneration, respectively. In view of these studies, the most likely explanation for the increased incorporation of [9,10-3H]-palmitate into the implanted tumor is that it reflects synthesis and/or turnover of cell membrane phospholipids at a greater rate in tumor tissue undergoing rapid proliferation than in the normal brain cell membranes. ~ 6.27,39
Another possible explanation for the increased radiolabeled palmitate incorporation is altered fatty acid transfer across the blood-tumor barrier as compared to the blood-brain barrier. This cannot be conclusively ruled out by our data, but several observations suggest that it does not account for the entire observed increased incorporation, and may influence the increase minimally. eminence :9) also had an increased incorporation of [9,10-3H]-palmitate relative to regions with an intact barrier, the rate of incorporation into these regions was small compared to maximum rates into tumor. In at least some non-barrier regions, such as paraventricular organs and choroid plexus, the relatively increased incorporation is also attributed to selective use of fatty acid as an energy source. 19.28.38 Such a use of fatty acid as an energy source is not attributed to the increased incorporation of [9,10-3H]-palmitate into tumor, because recent biochemical analysis showed that [9,10-3H]-palmitate is incorporated mainly into phospholipids of intracerebral tumor, with small amounts of radioactivity from metabolites (T Nariai, etal., unpublished data). Finally, the heterogeneous distribution of radioactivity in a tumor area reflects the distribution of active and non-necrotic tumor cells, which would not be expected if accumulated radioactivity were due to simple barrier opening.
Differences in regional cerebral blood flow between tumor and brain also can be excluded as contributing to elevated incorporation of radioactivity in tumor. Previous studies from our laboratory indicate that incorporation of [9,10-3H]-palmitate is not altered by increased cerebral blood flow induced by hypercapnia or neuronal activation, s'j7'23 Moreover, blood flow within intracerebral Walker 256 carcinosarcoma tumor is reported to be unchanged or decreased compared to the contralateral brain.
In agreement with our previous studies, 37 ' 41 we observed that sites of non-tumor glial proliferation also had increased [9,10-~H]-palmitate incorporation. Some of the increased incorporation into the hypoglossal nucleus during unilateral hypoglossal nerve regeneration was attributed to the glial proliferation of those regions? ~ Glial proliferation also was thought to account for the recovery of palmitate incorporation into the hippocampus CA1 pyramidal cell layer at 7 days after transient carotid artery occlusion, which had been reduced at 3 days? 7 Increased incorporation into the control lesion and into the brain surrounding the tumor was associated with gliosis and probably reflected increased turnover of glial-cell membranes. The increased radioactivity, however, was substantially lower than that in tumor tissue and could easily be distinguished from it.
Clinical Relevance
Our study suggests that the intravenous injection of a radiolabeled fatty acid can be a useful in vivo imaging method for studying cell proliferation of brain neoplasms in relation to lipid synthesis. This imaging approach in humans might supplement that of the 2-deoxyglucose method, ~3 which has been used to image brain tumors autoradiographically in animals 3"~ and in patients with positron emission tomography. 9 It has been suggested that glucose utilization by brain tumors correlates with their degree of malignancy? '4~ However, the undedying premise of the deoxyglucose approach (that phosphatase activity is minimaP 3) often is not satisfied when imaging brain tumors of non-neural or glial origin, which represents the majority of brain-sequestered tumors. On the other hand, the fatty acid incorporation model reflects synthesis and/or turnover of structural cellular elements containing lipids. It can be used to visualize cell proliferation directly, as the radiolabeled fatty acid is incorporated into membranes of active cells. Thus, it is possible to distinguish the active tumor cell from necrotic tissue with fine resolution. It may be used to detect the degree of malignancy of brain tumor or to determine the effectiveness of therapy, monitoring the rate of tumor membrane synthesis. As dl-erythro-9,10-[~8F]difluoro-palmitate 25 has recently been shown to have increased incorporation into a rat brain-tumor model, 3~ the fatty acid method might provide a new useful clinical imaging tool to study and diagnose brain tumors using positron emission tomography.
